The mutational status of KIT or PDGFRA is highly predictive of clinical response to imatinib, and patients with KIT exon 11 mutations have a significant longer progression free survival and overall survival than patients with KIT exon 9 mutations or wild-type GIST [11], [12]. This evidence concerns the gene PDGFRA and gastrointestinal stromal tumor.